Clinical benefit of depth of response for relapsed/refractory multiple myeloma patients treated on clinical trials: retrospective analysis from two tertiary centres

Br J Haematol. 2019 Jul;186(1):162-165. doi: 10.1111/bjh.15743. Epub 2018 Dec 28.

Authors

Esther H L Chan¹, Dunnya De-Silva², Adeline H F Lin¹, Neil Rabin³, Ashutosh Wechalekar³, Rakesh Popat², Wee Joo Chng¹, Kwee L Yong²

Affiliations

¹ Department of Haematology-Oncology, National University Hospital, Singapore, Singapore.
² Cancer Institute, University College London, London, UK.
³ Department of Haematology, University College London Hospital, London, UK.

PMID: 30592025
DOI: 10.1111/bjh.15743

No abstract available

Keywords: myeloma; response depth; survival; trials.

Publication types

Letter
Multicenter Study
Research Support, Non-U.S. Gov't

MeSH terms

Aged
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Clinical Trials as Topic
Drug Resistance, Neoplasm
Female
Humans
Male
Middle Aged
Multiple Myeloma / drug therapy*
Multiple Myeloma / pathology
Recurrence
Retrospective Studies
Tertiary Care Centers
Treatment Outcome